Polymer nanocomposite particles of S-nitrosoglutathione: A suitable formulation for protection and sustained oral delivery.

Abstract : S-nitrosoglutathione (GSNO) is a nitric oxide (NO) donor with therapeutic potential for cardiovascular disease treatment. Chronic oral treatment with GSNO is limited by high drug sensitivity to the environment and limited oral bioavailability, requiring the development of delivery systems able to sustain NO release. The present work describes new platforms based on polymer nanocomposite particles for the delivery of GSNO. Five types of optimized nanocomposite particles have been developed (three based on chitosan, two based on alginate sodium). Those nanocomposite particles encapsulate GSNO with high efficiency from 64% to 70% and an average size of 13 to 61μm compatible with oral delivery. Sustained release of GSNO in vitro was achieved. Indeed, chitosan nanocomposites discharged their payload within 24h; whereas alginate nanocomposites released GSNO more slowly (10% of GSNO was still remaining in the dosage form after 24h). Their cytocompatibility toward intestinal Caco-2 cells (MTT assay) was acceptable (IC50: 6.07 ± 0.07-9.46 ± 0.08mg/mL), demonstrating their suitability as oral delivery systems for GSNO. These delivery systems presented efficient GSNO loading and sustained release as well as cytocompatibility, showing their promise as a means of improving the oral bioavailability of GSNO and as a potential new treatment.
Type de document :
Article dans une revue
International Journal of Pharmaceutics, 2015, 495 (1), pp.354-61. 〈10.1016/j.ijpharm.2015.08.074〉
Liste complète des métadonnées

https://hal.univ-lorraine.fr/hal-01281137
Contributeur : Cithefor Ul <>
Soumis le : mardi 1 mars 2016 - 16:34:40
Dernière modification le : mercredi 27 juin 2018 - 17:06:01

Identifiants

Collections

Citation

Wen Wu, Caroline Gaucher, Isabelle Fries, Xian-Ming Hu, Philippe Maincent, et al.. Polymer nanocomposite particles of S-nitrosoglutathione: A suitable formulation for protection and sustained oral delivery.. International Journal of Pharmaceutics, 2015, 495 (1), pp.354-61. 〈10.1016/j.ijpharm.2015.08.074〉. 〈hal-01281137〉

Partager

Métriques

Consultations de la notice

67